Recent Updates
Recently added Catalysts

IgG4 Related Disease: one US-listed biotech with a clinical-stage programme

Immunology & InflammationUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$2.1Buniverse median $1.20B
Allocated capital$536M$2.1B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank198/299crowding rank 204

IgG4 Related Disease is uncontested. Zenas BioPharma (ZBIO) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Obexelimab in phase 3.

There is no public comparable to price it against. ZBIO spreads its $2.1B market cap across 4 indications, so $536M of it is allocated here.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$536M of allocated capital sits in IgG4 Related Disease, ranking it 198th of 299 indications by the money committed to it.

Companies developing drugs for IgG4 Related Disease 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
ZBIOZenas BioPharmaObexelimabPhase 31$2.1BNo4 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why IgG4 Related Disease counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. IgG4 Related Disease has one competitor and a median of $2.1B.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Systemic Sclerosis4 companies · $582M · median $540MOrphan cornerLupus Nephritis5 companies · $589M · median $516MOrphan cornerInflammatory Bowel Disease1 company · $609M · median $3.0BUncontestedComplement 3 Glomerulopathy1 company · $461M · median $1.4BUncontestedThrombotic Thrombocytopenic Purpura1 company · $461M · median $1.4BUncontestedImmune Thrombocytopenic Purpura2 companies · $458M · median $1.1BOrphan cornerChronic Graft-versus-Host Disease1 company · $458M · median $1.8BUncontestedPsoriatic Arthritis1 company · $646M · median $1.3BUncontested

IgG4 Related Disease pipeline questions

Which biotech companies are developing drugs for IgG4 Related Disease?

Zenas BioPharma (ZBIO, Obexelimab, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in IgG4 Related Disease.

How advanced is the IgG4 Related Disease pipeline?

Of the 1 clinical-stage programme in IgG4 Related Disease, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for IgG4 Related Disease?

No. ZBIO is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in IgG4 Related Disease, which is why the indication is classified as uncontested.

When is the next IgG4 Related Disease catalyst?

The next dated catalyst in IgG4 Related Disease is ZBIO on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map